Rebecca Kiely
Family · Deridder, LANPI 1801382031
Payments from drug & device makers
Across 55 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$241
- Astellas Pharma US Inc$146
- Novo Nordisk$99
- Lilly USA, LLC$75
- Otsuka America Pharmaceutical, Inc.$69
- AstraZeneca$61
- plus $408 from 15 others
What the payments were for
- Food & beverage$1,00992%
- Education$908%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 13 | $241 |
| Astellas Pharma US Inc | 4 | $146 |
| Novo Nordisk | 6 | $99 |
| Lilly USA, LLC | 4 | $75 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| AstraZeneca | 3 | $61 |
| Pfizer | 3 | $56 |
| Novartis | 3 | $53 |
| Boehringer Ingelheim | 3 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| Exact Sciences | 2 | $28 |
| Bayer | 1 | $24 |
| Abbott | 1 | $23 |
| Merck | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Organogenesis Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| GSK | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$1,099 in reported general payments places this provider in the 60th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 85 | $100,885 |
| LinzessLinaclotide | 91 | $54,545 |
| EliquisApixaban | 82 | $53,576 |
| MounjaroTirzepatide | 32 | $34,657 |
| RexultiBrexpiprazole | 15 | $27,407 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $26,200 |
| JardianceEmpagliflozin | 29 | $25,882 |
| JanuviaSitagliptin Phosphate | 21 | $18,530 |
| TrulicityDulaglutide | 14 | $14,594 |
| FarxigaDapagliflozin Propanediol | 11 | $10,559 |
| MultaqDronedarone Hcl | 12 | $10,148 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $9,350 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $8,336 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $6,565 |
| Gabapentin | 290 | $4,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $99 | $100,88585 claims |
| AbbVieLinzess | $241 | $54,54591 claims |
| PfizerEliquis | $56 | $53,57682 claims |
| Lilly USA, LLCMounjaro, Trulicity | $75 | $49,25246 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $52 | $34,21841 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $69 | $27,40715 claims |
| GSKTrelegy Ellipta | $17 | $26,20038 claims |
| MerckJanuvia | $19 | $18,53021 claims |
| AstraZenecaFarxiga, Symbicort | $61 | $17,12427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,610 family providers in Louisiana.
Other family in Deridder
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.